Clinical Trial Detail

NCT ID NCT02403505
Title Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair
Indications

prostate cancer

Therapies

Enzalutamide

Abiraterone

Prednisone

Degarelix

Age Groups: adult senior

No variant requirements are available.